Landmark International Brain Health Initiative Deploys NeuraLight's Biomarkers to Quantify Change in Brain Function
NeuraLight’s precision biomarkers will be integrated in the Healthy Brain Ageing (HeBA) initiative, a population-scale European program involving nearly 13,000 adults.
NeuraLight, a leader in precision brain function biomarkers, today announced that its platform will be deployed as part of the Healthy Brain Ageing (HeBA) study, a landmark European initiative advancing how brain function is measured and tracked across the aging population. The collaboration deploys NeuraLight’s precision brain function biomarkers in a population-scale program built to detect the earliest changes in the brain, up to a decade before symptoms appear.
HeBA is one of the most ambitious brain-aging efforts in Europe: a four-country program designed to identify people at risk of developing Parkinson's disease early. Spanning Germany, Austria, Spain and Luxembourg, the study focuses on adults aged 50 to 80 and has enrolled nearly 13,000 participants. It is supported by The Michael J. Fox Foundation, with its data platform led by the Luxembourg Centre for Systems Biomedicine (LCSB).
Understanding brain health requires understanding how brain function changes over time. Yet a critical gap remains: measuring these changes with enough sensitivity to detect early progression.
